ClinicalTrials.Veeva
Menu

Find clinical trials for Lung Cancer in Toronto, ON

CTV is a public benefit provided by Veeva Systems to help you find the most relevant clinical trials for you and your loved ones

Related conditions:

Non-Small-Cell Lung Carcinoma
Cancer
Carcinoma
Small Cell Lung Carcinoma
Squamous Cell Carcinoma of Head and Neck
Colorectal Cancer
Triple Negative Breast Cancer

Lung Cancer trials near Toronto, ON, CAN:

Autologous LN-145 in Patients With Metastatic Non-Small-Cell Lung Cancer

a prospective, open-label, multi-cohort, non-randomized, multicenter phase 2 study evaluating LN-145 in patients with metastatic non-small-cell lung...

Enrolling
Metastatic Non Small Cell Lung Cancer
Biological: LN-145

Phase 2

Iovance Biotherapeutics

Toronto, Ontario, Canada and 43 other locations

Osimertinib Then Chemotherapy in EGFR-mutated Lung Cancer with Osimertinib Third-line Rechallenge (OCELOT)

pemetrexed chemotherapy. The current standard of care for first-line Epidermal Growth Factor Receptor (EGFR) mutated Advanced Non-Small Cell Lung...

Enrolling
Non-Small Cell Lung Cancer
Drug: Osimertinib First-Line
Drug: Osimertinib Third-Line

Phase 2

Mark Vincent

Toronto, Ontario, Canada and 9 other locations

Pneumonitis Prevention Protocol Using Pentoxifylline and Α-tocopherol in Stage III Non-Small Cell Lung Cancer Patients Undergoing Chemoradiation (P4-PACIFIC)

Currently, the standard of care treatment for newly diagnosed, inoperable stage III non-small cell lung cancer is radiotherapy (RT) ...

Begins enrollment this month
Radiation Induced Lung Injury (RILI)
Non-Small Cell Lung Cancer
Other: Placebo
Other: α-Tocopherol

Phase 2

University Health Network, Toronto
University Health Network, Toronto

Toronto, Ontario, Canada

Study of DS-1062a Versus Docetaxel in Previously Treated Advanced or Metastatic Non-small Cell Lung Cancer With or Without Actionable Genomic Alterations (TROPION-LUNG01)

with previously treated advanced or metastatic non-small cell lung cancer (NSCLC) with or without actionable genomic alterations....

Active, not recruiting
Non-small Cell Lung Cancer
Drug: Docetaxel
Drug: DS-1062a

Phase 3

Daiichi Sankyo
Daiichi Sankyo

Toronto, Ontario, Canada and 209 other locations

Using ctDNA to Determine Therapies for Lung Cancer (ctDNA Lung RCT)

circulating tumour DNA (ctDNA) in the blood can help to predict whether giving adjuvant treatment after surgery can decrease the chance of the cancer...

Enrolling
Circulating Tumor DNA
Non Small Cell Lung Cancer
Drug: Gemcitabine
Drug: Carboplatin

Phase 2

University Health Network, Toronto
University Health Network, Toronto

Toronto, Ontario, Canada

Assessing an Oral EGFR Inhibitor, Sunvozertinib in Patients Who Have Advanced Non-small Cell Lung Cancer With EGFR or HER2 Mutation (WU-KONG1)

type of side effects may occur with the drug treatment. It will also measure the levels of drug in the body and preliminarily assess its anti-cancer...

Active, not recruiting
Non-Small Cell Lung Cancer
Drug: Sunvozertinib

Phase 1, Phase 2

Dizal Pharma

Toronto, Canada and 123 other locations

Neoadjuvant Immunoradiation for Resectable Non-Small Cell Lung Cancer

This is a pilot study of neoadjuvant 'immunoradiation' (durvalumab or durvalumab plus tremelimumab) administered every 4 weeks for 2 doses, concurren...

Active, not recruiting
Non-Small Cell Lung Cancer
Drug: Durvalumab
Drug: Standard of care adjuvant chemotherapy

Phase 2

Johns Hopkins Medicine
Johns Hopkins Medicine

Toronto, Ontario, Canada and 1 other location

Treatment of Pulmonary SUlcus, Pancoast and Chest Wall Non-small Cell Lung Cancer Employing Radiation, Immuno-oncology and Resection (SUPER)

The SUPER trial is a prospective Phase II trial. It is designed for patients with stage 2 or 3 non-small cell lung cancer (NSCLC) p...

Enrolling
Non-small Cell Lung Cancer (NSCLC)
Lung Cancer Patients
Radiation: Non-ablative oligofractionated radiation (NORT)
Drug: Durvalumab

Phase 2

Marc de Perrot

Toronto, Canada

New

An Adjuvant Study to Evaluate SMS001 (Paclitaxel) in Non-Small Cell Lung Cancer

This study evaluates the use of SMS001 in patients with lung cancer. SMS001 is a new form of drug Paclitaxel. Doctors want to decid ...

Not yet enrolling
Carcinoma, Non-Small-Cell Lung Cancer (NSCLC)
Drug: SMS001

Phase 2

ToLymph Inc.

Toronto, Ontario, Canada

Study of Nivolumab-Ipilimumab and cfDNA in Lung Cancer (ATLAS)

The purpose of this research study is to look at how effective two drugs, nivolumab and ipilimumab, are for people with non-small lung cancer...

Active, not recruiting
Non Small Cell Lung Cancer
Drug: Nivolumab
Drug: Ipilimumab

Phase 2

University Health Network, Toronto
University Health Network, Toronto

Toronto, Ontario, Canada

Clinical trials

Find clinical trialsTrials by location

Research sites

Find research sitesLearn about CTV for professionals

Resources

Contact CTV support

Legal

Privacy NoticeTerms
© Copyright 2024 Veeva Systems